Pooled analysis of two phase III studies provides prognostic indicators for clinical outcome after catumaxomab treatment for malignant ascites

被引：0
|
作者：
Bokemeyer, C. [1 ]
Heiss, M. M. [2 ]
Lordick, F. [3 ]
Parsons, S. L. [4 ]
Wimberger, P. [5 ]
Friccius-Quecke, H. [6 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[2] Univ Witten Herdecke, Krankenhaus Koln Merheim, Cologne, Germany
[3] Univ Klinikum, Leipzig, Germany
[4] Nottingham Univ Hosp NHS Trust, Nottingham, England
[5] Tech Univ Dresden, D-01062 Dresden, Germany
[6] Fresenius Biotech GmbH, Munich, Germany
来源：
ONKOLOGIE | 2013年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：273 / 274
页数：2
相关论文
共 50 条
  • [21] The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population)
    Jaeger, M.
    Schoberth, A.
    Hennig, M.
    Burges, A.
    Heiss, M.
    Wimberger, P.
    Schmalfeldt, B.
    Lindhofer, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
    Takashi Kadowaki
    Kazuyo Sasaki
    Manabu Ishii
    Miyuki Matsukawa
    Yoshiteru Ushirogawa
    Diabetes Therapy, 2018, 9 : 623 - 636
  • [23] Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS).
    Pietzner, Klaus
    Vergote, Ignace
    Santoro, Armando
    Marme, Frederik
    Rosenberg, Per
    Friccius-Quecke, Hilke
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: A pooled analysis of phase III studies
    Chapple, CR
    JOURNAL OF UROLOGY, 2004, 171 (04): : 130 - 130
  • [25] The Effect of Race on Treatment Response to Terlipressin in Patients with Hepatorenal Syndrome: A Pooled Analysis of 3 Phase III Clinical Studies
    Thuluvath, Paul J.
    Pyrsopoulos, Nikolaos T.
    Bhamidimarri, Kalyan Ram.
    Lim, Nicholas
    Jamil, Khurram
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S1083 - S1083
  • [26] Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis
    Bilton, Diana
    Bellon, Gabriel
    Charlton, Brett
    Cooper, Peter
    De Boeck, Kris
    Flume, Patrick A.
    Fox, Howard G.
    Gallagher, Charles G.
    Geller, David E.
    Haarman, Eric G.
    Hebestreit, Helge U.
    Kolbe, John
    Lapey, Allen
    Robinson, Phil
    Wu, Jian
    Zuckerman, Jonathan B.
    Aitken, Moira L.
    JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (04) : 367 - 376
  • [27] Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: A pooled analysis from two controlled phase III clinical studies
    Knopp, RH
    Dujovne, CA
    Le Beaut, A
    Lipka, LJ
    Suresh, R
    Veltri, EP
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (05) : 363 - 368
  • [28] Efficacy and Safety of Teneligliptin 40mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
    Kadowaki, Takashi
    Sasaki, Kazuyo
    Ishii, Manabu
    Matsukawa, Miyuki
    Ushirogawa, Yoshiteru
    DIABETES THERAPY, 2018, 9 (02) : 623 - 636
  • [29] Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies
    Kadowaki, Takashi
    Marubayashi, Fuyuhiko
    Yokota, Shoko
    Katoh, Makoto
    Iijima, Hiroaki
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (07) : 971 - 981
  • [30] The trifunctional antibody catumaxomab: Correlation between immunological response and clinical outcome-New analysis of a pivotal phase II/III study
    Ott, M. G.
    Lindhofer, H.
    Linke, R. G.
    Hennig, M.
    Martinius, H.
    Klein, A.
    Seimetz, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345